Thrashed by a 'surprise' rival, Sanofi writes off $2B on soured hemophilia deal
The meteoric rise of Dupixent has swelled Q2 revenue at Sanofi, pushing up estimates for this year’s sales growth and grabbing analysts’ attention Monday. But the pharma giant still has some sour news to unload.
Sanofi wrote off $2 billion after watching the market for its hemophilia drug Eloctate shrivel in the face of Roche’s new star, Hemlibra. Sales dropped 11% and appear pointed firmly south.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
